Risk factors for chronic rejection in pediatric renal transplant recipients--a single-center experience. 1997

P E Birk, and A J Matas, and K J Gillingham, and S M Mauer, and J S Najarian, and B M Chavers
Department of Pediatrics, University of Minnesota, Minneapolis 55455-0392, USA.

Chronic rejection (CR) is the most common cause of graft loss beyond the 1st posttransplant year. The aim of this analysis was to identify the risk factors for the development of CR in pediatric renal transplant recipients. Between June 1984 and March 1994, 217 renal transplants were performed in children at our center. Immunosuppression included prednisone, azathioprine, cyclosporine (CsA), and prophylactic antibody. Using multivariate analysis, we studied the impact of the following variables on the development of biopsy-proven CR: age at transplant (< or = 5 years, > 5 years), gender, race, transplant number (primary, retransplant), donor source (cadaver, living donor), donor age (< 20 years, 20-49 years, > 49 years), number of ABDR mismatches (0, 1-2, 3-4, 5-6), number of DR mismatches (0, 1, 2), percentage peak panel reactive antibody (PRA) (< or = 50%, > 50%), percentage PRA at transplantation (< or = 50%, > 50%), dialysis pretransplant, preservation time > 24 h, acute tubular necrosis requiring dialysis, initial CsA dosage (< or = 5 mg/kg per day, > 5 mg/kg per day), CsA dosage at 1 year posttransplant (< or = 5 mg/kg per day, > 5 mg/kg per day), acute rejection (AR), number of AR episodes (ARE) (1, > 1), timing of AR (< or = 6 months, > 6 months), reversibility of AR (complete, partial), and infection [cytomegalovirus (CMV), non-CMV viral, bacterial]. Risk factors for the development of CR in pediatric renal transplant recipients were: AR (P < 0.0001, odds ratio 19.4), multiple ARE (> 1 vs. 1) (P < 0.0001, odds ratio 30.1), and high percentage peak PRA (> 50%) (P < 0.03, odds ratio 3.6).

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor

Related Publications

P E Birk, and A J Matas, and K J Gillingham, and S M Mauer, and J S Najarian, and B M Chavers
March 2011, Transplantation proceedings,
P E Birk, and A J Matas, and K J Gillingham, and S M Mauer, and J S Najarian, and B M Chavers
January 2019, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation,
P E Birk, and A J Matas, and K J Gillingham, and S M Mauer, and J S Najarian, and B M Chavers
December 1996, Pediatric nephrology (Berlin, Germany),
P E Birk, and A J Matas, and K J Gillingham, and S M Mauer, and J S Najarian, and B M Chavers
June 1994, Clinical transplantation,
P E Birk, and A J Matas, and K J Gillingham, and S M Mauer, and J S Najarian, and B M Chavers
September 2022, Transplantation proceedings,
P E Birk, and A J Matas, and K J Gillingham, and S M Mauer, and J S Najarian, and B M Chavers
August 2001, Pediatric transplantation,
P E Birk, and A J Matas, and K J Gillingham, and S M Mauer, and J S Najarian, and B M Chavers
August 2019, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation,
P E Birk, and A J Matas, and K J Gillingham, and S M Mauer, and J S Najarian, and B M Chavers
February 2013, Transplant international : official journal of the European Society for Organ Transplantation,
P E Birk, and A J Matas, and K J Gillingham, and S M Mauer, and J S Najarian, and B M Chavers
March 2012, Pediatric transplantation,
P E Birk, and A J Matas, and K J Gillingham, and S M Mauer, and J S Najarian, and B M Chavers
September 2016, Transplantation proceedings,
Copied contents to your clipboard!